Loading...
Loading...
DXCM| Name | Value |
|---|---|
| Revenues | 1,034.5M |
| Cost of Revenue | 377.9M |
| Gross Profit | 656.6M |
| Operating Expense | 439.7M |
| Operating I/L | 216.9M |
| Other Income/Expense | 29.3M |
| Interest Income | 33.8M |
| Pretax | 246.2M |
| Income Tax Expense | -10.1M |
| Net Income/Loss | 256.3M |
DexCom, Inc. specializes in developing and commercializing continuous glucose monitoring (CGM) systems for diabetes management. Its flagship product, DexCom G6, is an integrated CGM system that replaces finger stick blood glucose testing. The company also offers Dexcom Real-Time API for third-party developers to integrate CGM data into digital health applications, Dexcom ONE for diabetes treatment decisions, and Dexcom Share for remote monitoring. DexCom generates revenue by marketing its products directly to endocrinologists, physicians, and diabetes educators. Additionally, the company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products.
